Olema Pharmaceuticals Q2 net loss widens on higher clinical trial spending

Olema Pharmaceuticals

10/08/2026 21:10

Overview
US biopharmaceutical firm's Q2 net loss widened yr/yr due to higher clinical development spending
Company completed enrollment in pivotal Phase 3 OPERA-01 trial for metastatic breast cancer
Olema announced clinical trial collaboration with Bayer for prostate cancer therapy

Outlook
Company expects top-line data from OPERA-01 trial in first quarter of 2027
Olema plans to initiate enrollment in OP-3136/darolutamide trial in Q4 2026
Company is preparing for potential commercial launch of palazestrant as monotherapy

Result Drivers
HIGHER R&D SPENDING - Co said increased R&D expenses were mainly due to higher spending on clinical development for palazestrant and OP-3136, and increased personnel costs
HIGHER G&A EXPENSES - Co attributed increased G&A costs to investment in personnel and infrastructure for late-stage clinical development and anticipated commercial operations

Company press release: ID:nGNX14Mntl

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$63.20 mln
 
Q2 Operating Expenses
 
$67.18 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Olema Pharmaceuticals, Inc. is $40.00, about 232% above its August 7 closing price of $12.05

Reuters Recommended Reads
Aug 10 - Cogent Biosciences Q2 net loss widens on higher expenses
Aug 10 - Oruka Therapeutics Q2 net loss widens on higher R&D costs
Aug 10 - Ireland's Theravance Biopharma Q2 revenue rises 11% but misses estimates

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)